Items where authors include "Popat, R"

Article

Royle, K-L orcid.org/0000-0003-0225-1199, Coulson, AB, Ramasamy, K et al. (26 more authors) (2022) Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II/III randomised controlled trial. BMJ Open, 12 (11). e063037. ISSN 2044-6055

Morris, TCM, Drake, MB, Kettle, PJ et al. (12 more authors) (2021) How to Simplify the Evaluation of Newly Introduced Chemotherapeutic Interventions in Myeloma. Clinical hematology international, 3 (1). pp. 27-33. ISSN 2590-0048

Koutoukidis, DA, Land, J, Hackshaw, A et al. (14 more authors) (2020) Fatigue, quality of life and physical fitness following an exercise intervention in multiple myeloma survivors (MASCOT): an exploratory randomised Phase 2 trial utilising a modified Zelen design. British Journal of Cancer, 123 (2). pp. 187-195. ISSN 0007-0920

Cook, G orcid.org/0000-0003-0223-3652, Ashcroft, AJ, Pratt, G et al. (13 more authors) (2020) Real‐world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID‐19 disease) in patients with Multiple Myeloma receiving systemic anti‐cancer therapy. British Journal of Haematology. ISSN 0007-1048

Popat, R, Brown, SR, Flanagan, L et al. (10 more authors) (2019) Extended follow‐up and the feasibility of Panobinostat maintenance for patients with Relapsed Multiple Myeloma treated with Bortezomib, Thalidomide, Dexamethasone plus Panobinostat (MUK six open label, multi‐centre phase I/II Clinical Trial). British Journal of Haematology, 185 (3). pp. 573-578. ISSN 0007-1048

Chapman, MA, Sive, J, Ambrose, J et al. (27 more authors) (2018) RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature. Blood, 132 (20). pp. 2154-2165. ISSN 0006-4971

Popat, R, Brown, SR, Flanagan, L et al. (9 more authors) (2016) Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial. The Lancet Haematology, 3 (12). e572-e580. ISSN 2352-3026

Proceedings Paper

Yong, K, Royle, K-L orcid.org/0000-0003-0225-1199, Ramasamy, K et al. (23 more authors) (2022) Risk-Adapted Therapy Directed According to Response (RADAR, UK-MRA Myeloma XV) - Comparing MRD-Guided Treatment Escalation and De-Escalation Strategies in Patients with Newly Diagnosed Myeloma Suitable for Stem Cell Transplantation. In: Blood. 64th ASH Annual Meeting, 10-13 Dec 2022, New Orleans, Louisiana. American Society of Hematology , pp. 1844-1846.

Sowter, J, Koutoukidis, DA, Heinrich, M et al. (13 more authors) (2018) Fatigue, Quality of Life, and Physical Fitness Following an Exercise Intervention in Survivors of Multiple Myeloma: A Randomised Controlled Trial Using a Zelen Design. In: Blood. 60th Annual Meeting of the American Society of Hematology, 01-04 Dec 2018, San Diego, Calif., U.S.A.. American Society of Hematology .